Oppenheimer Asset Management Inc. trimmed its position in shares of GlaxoSmithKline plc (NYSE:GSK) by 1.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 240,460 shares of the pharmaceutical company’s stock after selling 2,683 shares during the period. Oppenheimer Asset Management Inc.’s holdings in GlaxoSmithKline were worth $9,659,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. Optimum Investment Advisors boosted its stake in GlaxoSmithKline by 88.5% during the 3rd quarter. Optimum Investment Advisors now owns 2,749 shares of the pharmaceutical company’s stock valued at $110,000 after purchasing an additional 1,291 shares during the period. Kiley Juergens Wealth Management LLC acquired a new position in GlaxoSmithKline during the 2nd quarter valued at about $113,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new position in GlaxoSmithKline during the 2nd quarter valued at about $134,000. Toronto Dominion Bank boosted its stake in GlaxoSmithKline by 46.0% during the 2nd quarter. Toronto Dominion Bank now owns 4,600 shares of the pharmaceutical company’s stock valued at $186,000 after purchasing an additional 1,450 shares during the period. Finally, Amussen Hunsaker Associates LLC acquired a new position in GlaxoSmithKline during the 2nd quarter valued at about $193,000. 11.00% of the stock is owned by hedge funds and other institutional investors.
NYSE GSK opened at $39.32 on Friday. The company has a debt-to-equity ratio of 8.13, a quick ratio of 0.61 and a current ratio of 0.94. GlaxoSmithKline plc has a 12 month low of $34.52 and a 12 month high of $42.36. The company has a market capitalization of $98.03 billion, a P/E ratio of 13.65, a price-to-earnings-growth ratio of 1.93 and a beta of 0.87.
In other GlaxoSmithKline news, insider Plc Glaxosmithkline bought 148,818 shares of the company’s stock in a transaction that occurred on Monday, July 30th. The shares were acquired at an average cost of $11.00 per share, for a total transaction of $1,636,998.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 10.00% of the stock is owned by insiders.
GSK has been the subject of a number of research analyst reports. TheStreet raised shares of GlaxoSmithKline from a “c” rating to a “b” rating in a research note on Monday, August 6th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research note on Friday, July 20th. Deutsche Bank reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research note on Wednesday, August 1st. Wolfe Research initiated coverage on shares of GlaxoSmithKline in a research note on Tuesday. They issued a “market perform” rating for the company. Finally, Bank of America set a $40.00 price target on shares of GlaxoSmithKline and gave the stock a “hold” rating in a research note on Wednesday, July 25th. Twelve equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. GlaxoSmithKline has an average rating of “Hold” and a consensus target price of $41.57.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Article: How to Invest in Growth Stocks
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.